Navigation Links
Colorcon Acquires Pharmaceutical Excipient Company - NP Pharm

HARLEYSVILLE, Pa., April 22 /PRNewswire/ -- Colorcon, Inc. today announced the acquisition of the full-service pharmaceutical excipient company, NP Pharm, a Division of Ethypharm.  This acquisition expands Colorcon's global excipient product offerings in the pharmaceutical and nutritional markets.

The addition of NP Pharm SUGLETS® sugar spheres complements Colorcon's SureSpheres® sugar spheres product line and barrier membrane systems for multiparticulates.  Colorcon will now have two production facilities for sugar spheres offering critical business continuity planning for their customer base.  ETHISPHERES® microcrystalline cellulose pellets, NPTAB® neutral pellets for direct compression, and other excipient products are also added to the Colorcon product portfolio as a result of this acquisition.

The headquarters and main production facilities of NP Pharm, located in Bazainville, France, will become an integral part of the Colorcon network of manufacturing sites.

William Motzer, Colorcon Chief Executive Officer states, "We are excited about this opportunity to expand Colorcon's product offerings and leverage our global distribution, technical service and sales infrastructure."

Newly appointed Chairman and CEO of the Management Board of Ethypharm, Hugues Lecat states, "We are delighted to see NP Pharm join Colorcon, Inc.  The new shareholder will permit NP Pharm to reinforce its development and growth projects.  This divestiture will enable us to go on investing in the growth of Ethypharm, in line with our strategy.  Ethypharm will continue to invest in its R&D sites, notably that of Grand Quevilly, France, our most recent state-of-the-art manufacturing plant, in which we have invested over 15 million Euros over the last two years."

About Colorcon, Inc.

Colorcon is a world leader in the development, supply and technical support of formulated film coating systems, modified release technologies, and functional excipients for the pharmaceutical industry. Our best-in-class products and technologies are complemented by our value-added services, which support all phases of solid oral dose design and development.

About Ethypharm

Ethypharm is one of the leading pharmaceutical companies dedicated to the development of innovative medicines.  Its patented technologies offer multiple benefits for patients by improving efficacy, administration, compliance, and reducing side-effects. Ethypharm provides its clients with solutions for the life cycle management of their drugs. The company has one of the broadest portfolios of technologies to become the worldwide privileged partner of pharmaceutical companies. Ethypharm offers customized solutions for the development of the medicines of the future.

SOURCE Colorcon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance
2. Perrigo Acquires Infant Formula Manufacturer PBM Holdings for $808 Million
3. Cambrex Acquires IEP GmbH
4. Essilor Acquires FGX International, Becoming a Major Player in a New Fast-Growing Market
5. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
6. Bioniche Pharma Acquires Seven New Products From GeneraMedix Inc.
7. STD Med Inc. Acquires Facility for Manufacturing and Start-Ups
8. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
9. Tongjitang Chinese Medicines Acquires Guiyang Liquor Factory
10. Advanced Health Media Acquires Advogent
11. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
Post Your Comments:
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... MINNEAPOLIS , Nov. 25, 2015  ARKRAY ... care products, continues to provide evidence demonstrating the accuracy ... the World Congress on Insulin Resistance, Diabetes and Cardiovascular ... showed that both the Company,s GLUCOCARD ® 01 ... met high accuracy requirements. The ability to accurately measure ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):